Tempus AI Buys Personalis for $1.5B as Insiders Sell

A $1.5 billion deal and a founder who keeps selling

The founder and CEO of an AI healthcare company just agreed to spend $1.5 billion buying a competitor. At the same time, his own dossier shows roughly $106 million of net insider selling behind him. Tempus AI agreed to acquire Personalis for a total enterprise value of $1.5 billion, net of the stake it already owns, while NexusAlert’s Company Dossier shows net insider selling of $105.9 million led by founder CEO Eric Lefkofsky.

The 8-K hit the wire the morning of July 20, 2026. Tempus AI, ticker $TEM, is the AI precision oncology company Lefkofsky founded after co-founding Groupon. Personalis, ticker $PSNL, makes the NeXT Personal test for molecular residual disease, the trace of cancer that can linger after treatment. Tempus already partnered with Personalis back in November 2023 and commercializes that test today. Now it wants the whole company.

What the filing actually says

Personalis shareholders will receive $16.25 per share, a 6% premium to Friday’s close and a 28% premium to the unaffected 30-day average. The deal is structured as a 100% stock transaction, with Tempus holding the option to pay up to 50% in cash and a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share.

The AI Analysis on the alert pulled one detail most headlines skipped: Personalis reported preliminary second quarter revenue of $22.4 million and a 33% quarter over quarter jump in clinical test volumes, with 10,384 tests delivered. Management expects the transaction to close in late 2026 or early 2027, pending a Personalis shareholder vote and regulatory clearances.

So is the insider selling a red flag?

Not the way it looks at first glance. The Dossier’s net figure is real, and most of it is the C-suite: $103.6 million of the $105.9 million in sell value came from C-suite filers, with 24 Form 144 notices covering $78.9 million of planned sales still on file. On a raw screen, that reads like a management team heading for the exits right as it makes a bet-the-company acquisition.

Read the filings underneath the number, though, and the story softens. Lefkofsky’s sales run through a Rule 10b5-1 trading plan his entities adopted in early 2025. That is the pre-scheduled, automatic kind of selling that executes on a calendar regardless of what the stock does, which is precisely why it exists: to separate routine diversification from opportunistic timing. He also still holds tens of millions of Tempus shares across his holding entities. A founder cashing out on a fixed schedule while keeping a nine-figure stake is not the same as a founder fleeing.

The number that actually deserves your attention

The selling is a distraction. The signal is the scorecard. Tempus scores Insider Conviction 1.4 out of 10, in the bottom 14% of companies, and Earnings Quality 2.5, in the bottom 25%, for an overall dossier rating of 14.5 out of 40, or below average. This is a company paying a premium in its own stock, not cash, while its fundamentals rate weak.

That is the real question for a Personalis holder deciding whether to take the exchange: you are trading a defined cash-equivalent value of $16.25 for a floating slice of a richly valued acquirer whose own dossier is soft. The strategic logic is sound. Owning more MRD capability inside an AI oncology platform is a coherent bet. But the currency funding it is Tempus stock, and Tempus stock is the thing the scorecard is cautious about.

A pre-scheduled sale is noise. The conviction score behind it is the signal. Classify the transaction before you react to the total.

Why this is a NexusAlert story

News wires reported the $1.5 billion price the moment it crossed. What they did not do was hand you the insider context in the same glance. NexusAlert flagged the 8-K the morning it filed, and the Company Dossier put the net insider flow, the Form 144 backlog, the named seller, and the five pillar scores on one page, so the acquisition headline and the caution underneath it sit side by side.

That is the difference between reading a press release and reading the filing. The press release tells you Tempus is buying growth. The filing trail tells you how its own insiders and its own numbers are positioned while it does.

Create a free NexusAlert account and put any ticker’s insider activity, institutional flow, and pillar scores on one screen.

Sources

• Tempus AI Form 8-K, Exhibit 99.1 (SEC EDGAR)
• Tempus to Acquire Personalis, More Tightly Integrating MRD (Business Wire via Morningstar)
• Tempus to acquire Personalis for $1.5 billion (Investing.com)
• Tempus AI to Buy Cancer-Tech Firm Personalis (Bloomberg)
• Lefkofsky entities sell Tempus AI shares under 10b5-1 plan (StockTitan Form 4)